Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

@article{Ward1987PentoxifyllineAR,
  title={Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.},
  author={A. Ward and S. Clissold},
  journal={Drugs},
  year={1987},
  volume={34 1},
  pages={
          50-97
        }
}
Pentoxifylline (oxpentifylline) is an orally active haemorheological agent for the treatment of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation. Pentoxifylline acts primarily by increasing red blood cell deformability, by reducing blood viscosity and by decreasing the potential for platelet aggregation and thrombus formation. Extensive open and placebo-controlled studies have shown that pentoxifylline 600 to… Expand
PENTOXIFYLLINE IN ACUTE ISCHEMIC STROKE PATIENTS WITH BLOOD HYPERVISCOSITY
TLDR
Pentoxifylline decreased blood viscosity and improved clinical outcome in this patient series of strokes in patients with blood hyperviscosity. Expand
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.
TLDR
Overall, buflomedil at dosages of up to 600 mg/day has been very well tolerated and discontinuation of therapy has rarely been necessary, and would seem to be a useful adjunct to conservative treatment in patients with mild-to-moderate peripheral vascular disease and/or cerebrovascular insufficiency, and well worth a try in Patients with more severe peripheral disease unable to undergo surgery. Expand
Comparative Evaluation of Pentoxifylline, Buflomedil, and Nifedipine in the Treatment of Intermittent Claudication of the Lower Limbs
TLDR
Pentoxifylline proved more effective than the other drugs tested in improving distal pressure and resting microcirculatory blood flow, and increasing postexercise distal flow, ratios, and pressures and enabling faster recuperation of basal pulse rates. Expand
Clinical Update on Pentoxifylline Therapy for Diabetes-Induced Peripheral Vascular Disease
TLDR
Studies show that pentoxifylline is an alternative to vascular surgery in the management of peripheral vascular disease in diabetic patients, particularly in those with chronic ulceration of the lower extremities that does not heal despite other optimal treatment regimens. Expand
Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice.
  • D. Honess, I. Dennis, N. Bleehen
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1993
TLDR
The data indicate that pentoxifylline is effective at increasing relative tumour perfusion, with minimal effects on other tissues, and this increase is reflected in improved radiosensitivity, and the doses at which the drug is effective are compatible with the mechanism being modification of blood cell deformability. Expand
Drug Treatment of Intermittent Claudication
TLDR
Clinical trials indicate many other drugs may relieve the symptoms of intermittent claudication and novel approaches including angiogenesis mediated by growth factors, are currently under investigation. Expand
Dosing regimen and hematologic effects of pentoxifylline and its active metabolites in normal dogs.
TLDR
The findings suggest that a 12-hour dosing regimen is appropriate for pentoxifylline in dogs and the lack of hematologic effects suggests that the immunologic effects of pentoxifyinglline may be of more importance in dogs. Expand
Hemodialysis, membrane-related neutrophil dysfunctions, and pentoxifylline — A pilot study
TLDR
Combined oral and intravenous treatment with pentoxifylline prevented neither leukopenia nor neutrophil degranulation during the time interval studied and may be due to the small number of cases studied and to difficulties in reaching effective plasma levels without side effects. Expand
Pentoxifylline in Liver Ischemia and Reperfusion
TLDR
Pentoxifylline has shown positive effects in liver ischemia and reperfusion injury, and the main mechanism seems to be associated with the inhibition of TNF-α. Expand
Clinical Pharmacokinetics of Ketorolac Tromethamine
TLDR
Ketorolac is a new chiral nonsteroidal anti-inflammatory drug (NSAID) which is marketed for analgesia as the racemate and has a volume of distribution comparable with those of other NSAIDs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 347 REFERENCES
Studies of the Clinical Pharmacology and Therapeutic Efficacy of Pentoxifylline in Peripheral Obstructive Arterial Disease
TLDR
The clinical benefit of pentoxifylline (Trental 400) treatment was demonstrated by the significantly superior increase in walking capacity in comparison to placebo in the controlled study. Expand
Pentoxifylline--a new drug for the treatment of intermittent claudication.
TLDR
The hypothesis that Pentoxifylline in doses of 400 mg TDS reduces blood viscosity by improving red cell flexibility, and thereby enhances blood flow in patients with COAD, is supported. Expand
Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease.
TLDR
Pentoxifylline was used in the treatment of 90 patients with atherosclerosis-induced chronic peripheral arterial occlusive disease and diabetic vascular disorders in the lower extremities for whom surgical reconstructive treatment was not indicated and who had shown inadequate response to previous therapy. Expand
Clinical Pharmacology of Pentoxifylline With Special Reference to Its Hemorrheologic Effect for the Treatment of Intermittent Claudication
TLDR
I n 1976, one of the authors (D.M.A.) proposed a classification of drugs for the treatment of intermittent claudication, and the situation in the United States is essentially unchanged in that no vasodilator was available. Expand
Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin.
TLDR
Patients with peripheral arterial disease and laboratory data provided no evidence to suggest any adverse effect of either treatment, and the clear improvement shown for both variables was greater and statistically significant after treatment with pentoxifylline. Expand
Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease
TLDR
Pentoxifylline appears to be useful in the medical management of patients with moderate to severe chronic occlusive arterial disease; future controlled trials in such patients are now justified. Expand
Continuous Infusion Treatment with Pentoxifylline in Patients with Severe Peripheral Vascular Occlusive Disease
TLDR
The results of this study indicate that the continuous infusion of pentoxifyl line is safe and effective in improving the condition of patients with severe pe ripheral vascular disease. Expand
Clinical use of pentoxifylline in haemorrhagic disorders of the retina.
TLDR
It is suggested that pentoxifylline is effective in preventing retinal or intra-vitreal neovascularization caused by retinal ischaemia and in hastening recovery from these diseases. Expand
The use of pentoxifylline in the treatment of ischaemic heart disease
TLDR
Pentoxifylline produced a positive effect on the ECG, deceleration of pulse rate and normalization of R and T waves being registered in 22 patients, and tachycardia disappeared or was diminished considerably in 20 of 26 patients in whom it had been detected previously. Expand
Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication?
TLDR
It is concluded that oxpentifylline, when taken in oral form at the dose used in this study, increased erythrocyte deformability without conferring any clinical or haemorrheological benefit to patients with intermittent claudication. Expand
...
1
2
3
4
5
...